STOCK TITAN

Theralase Technologies Inc. - TLTFF STOCK NEWS

Welcome to our dedicated news page for Theralase Technologies (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theralase Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theralase Technologies's position in the market.

Rhea-AI Summary
Theralase Technologies Inc. donates Theralase TLC-2400 Cool Laser Therapy systems to aid in Parkinson's Disease research at the University of Windsor. The collaboration aims to study the potential of CLT in treating Parkinson's, showcasing positive outcomes in preliminary studies and animal experiments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Theralase Technologies Inc. announces the appointment of Dr. Michael Jewett as an independent consultant to assist in the completion of patient enrollment in the Phase II clinical study for the treatment of non-muscle invasive bladder cancer. The company aims to enroll 100 patients by the end of 2024 to potentially secure regulatory approval by 2027. Dr. Jewett's impressive background in surgical oncology and his advocacy for patient-centered care make him a valuable addition to the team. Theralase's photodynamic therapy technology has shown promising efficacy and safety profiles in treating BCG-Unresponsive NMIBC CIS, with high response rates and minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Theralase Technologies Inc. successfully closed a non-brokered private placement offering of units, issuing 6,666,670 units at a price of $CAN 0.18 per unit for gross proceeds of approximately $CAN 1,200,000. The company plans to use the proceeds for furthering the Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research and development of Rutherrin, working capital, and general corporate purposes. The offering is subject to a four-month hold period and final acceptance from the TSX Venture Exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Summary
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, showcasing interim clinical data that exceeds International Bladder Cancer Group guidelines. The study demonstrates a complete response of 54% at 6 months, 38% at 12 months, and 37% at 15 months. Additionally, 62% of patients who received the optimized treatment achieved a complete response at 90 days, and 68% achieved a total response. The company has submitted a pre-Breakthrough Designation submission to the FDA and plans to complete enrollment and delivery of the primary study treatment for all patients in 2024, aiming for potential Health Canada and FDA approval by 2026 / 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Theralase Technologies Inc. (TLT) released its 3Q2023 unaudited condensed interim consolidated Financial Statements, reporting a 13% decrease in total revenue. The company experienced a 32% decrease in net research and development expenses for the Drug Division, but a 36% increase in administrative expenses. Theralase also closed a non-brokered private placement, raising over $1.1 million in gross proceeds. The company is working on a Break Through Designation submission to the FDA and provided preliminary clinical data for Study II, demonstrating promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Summary
Theralase Technologies Inc. (TLT) successfully closed a non-brokered private placement offering, raising approximately $CAN 1,170,000 to further the Phase II Non-Muscle Invasive Bladder Cancer clinical study and for working capital needs. The Corporation issued 5,318,183 Units at $0.22 per Unit, each consisting of one Common Share and one Warrant. Insider subscriptions accounted for $101,482 of the gross proceeds, constituting a related party transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
Rhea-AI Summary
Theralase® Technologies Inc. (TLT) has initiated a non-brokered private placement of units to raise up to $CAN 1.5 M. Each unit is priced at $CAN 0.22 and includes one common share and one common share purchase warrant. The company plans to use the proceeds for the Phase II Non-Muscle Invasive Bladder Cancer clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Theralase Technologies Inc. announces an agreement with Research Capital Corporation for a brokered offering of units at a price of C$0.22 per unit. The offering will raise a minimum of C$3,500,000 and a maximum of C$5,300,000. The company plans to use the proceeds for a clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.05%
Tags
none
-
Rhea-AI Summary
Theralase Technologies has been granted a Clinical Trial Application Amendment by Health Canada for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer clinical study. The optimization includes post-study monitoring of response, optional maintenance treatments, and central pathology laboratory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
Rhea-AI Summary
Theralase Technologies files US patent for combining immunotherapy drugs with its PDC technology for increased cancer destruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Theralase Technologies Inc.

OTC:TLTFF

TLTFF Rankings

TLTFF Stock Data

40.02M
211.97M
8.14%
0%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Canada
East York